Mark Joseph Holterman

 

Mark Joseph Holterman

M.D.

1980 Yale University – B.A., Biology, cum laude
1987 University of Virginia – Ph.D.
1988 University of Virginia – M.D.

TRAINING AND EMPLOYMENT:
6/88 – 6/93   Resident in General Surgery
University of Virginia Health Sciences
Charlottesville, Virginia
7/93 – 6/95   Fellowship in Pediatric Surgery,
Children’s Hospital and Medical Center,
Instructor in Surgery, Univ. of Washington,
Seattle, Washington
8/95 – 6/97   Research Associate, Clinical Research Institute of Montreal
7/97-12/10   Assistant then Associate Professor, University of Illinois at Chicago

8/00-7/12     Attending Pediatric Surgeon, Rush University Medical Center

8/08-12/10   Surgeon-in-Chief, Advocate Christ Children’s Hospital, Oak Lawn, IL

1/11- 1/18    Full Professor, University of Illinois College of Medicine

1/18-present CEO and Founder of Mariam Life (nonprofit,technology development and distribution).

5/18-present CEO and Founder MariamTek, Inc. Technology development and holding company,

9/2007-present Board member and founding member of the International Pediatric Specialist Alliance for Children of Vietnam (IPSAC-VN) Non-Profit with the mission of increasing surgical capacity for the children of Vietnam. Involves surgical trips to Vietnam twice a year.

LICENSURE AND CERTIFICATE:

Illinois license # 036-095619

Maine License-Active, but I never practiced there

Montana License-Active, but I never practiced there

National Practitioner Identification # 1033168273

General Surgery Board certificate # 38996

Pediatric Surgery Board certificate # 726

Honors and Awards:

9/76 – 5/80 National Merit Scholar, Yale University

9/80 – 12/88 NIH Medical Scientist Training Program

6/2001 – 6/2003 American Diabetes Association, Innovative

                          Research Award

Memberships

Fellow, American College of Surgeons

Fellow, American Academy of Pediatrics, Surgical Section

American Pediatric Surgery Association

Pacific Association of Pediatric Surgeons

Bibliography

 

1.) Beaty BJ, Holterman MJ, Tabachnik W, Rozhon EJ, and Bishop DHL:!

“Molecular basis of Bunyavirus transmission by mosquitoes: Role of the middle-sized

RNA segment.” Science, 211:1433-1434, (1981).

2) Engelhard VH, Powers G, Moore LC, Holterman MJ, and Correa-Freire MC: “Cytotoxic

T lymphocyte recognition of HLA – A/B antigens introduced into EL4 cells by cell-liposome

fusion.” J. Immunol, 132:69, (1984).

3) Engelhard VH, Yannelli JR, Evans GA, Walk SA, and Holterman MJ:!

“Construction of novel class I histocompatibility antigens by interspecies exon shuffling.”

  1. Immunol, 134:4218, (1985).

4) Holterman MJ and Engelhard, VH: “HLA antigens expressed on murine cells are preferentially

recognized by murine cytotoxic T cells in the context of the H-2 major histocompatibility

complex.” Proc. Nat. Acad. Sci., 83:9699, (1986).

5) Bernhard E, Le AT, Yannelli JR, Holterman MJ, Hogan KT, Parham P and Engelhard

VH: “The ability of cytotoxic T cells to recognize HLA-A2.1 or HLA-B7 antigens expressed

on murine cells correlates with their epitope specificity.” J. Immunol, 139:3614,

(1987).

6) Engelhard VH, Le AT and Holterman MJ: “Species-specific structural differences in the

a1 and a2 domains determine the frequency of murine cytotoxic T cell precursors stimulated

by human and murine class I molecules.” J. Immunol., 141:1835, (1988).

7) Le, AT, Bernhard, E, Holterman MJ, Parham P, Lacy E and Engelhard VH: “Cytotoxic

T cell responses in HLA-A2.1 transgenic mice: Recognition of HLA alloantigens and utilization

of HLA-A2.1 as a restriction element.” J. Immunol, 142:1366, (1988).

8) Cox TD, Winters WD, Holterman MJ, Hatch EI, and Skarin RM, “Neonatal bowel ischemia

attributable to an umbilical arteriovenous fistula: imaging findings”, Am J

Roentgenology 165(4):940-2, (1995).W

9) Waldhausen JHT, Holterman MJ and Tapper D., “Identification and Surgical Management

of Cystic Retroperitoneal Lymphangiomas in Children”, Ped Surg Int. 11:283-85,

(1996).

10) Waldhausen JHT, Holterman MJ and Sawin RS, “Surgical Implications of Necrotizing

Fasciitis in Children with Chicken Pox”, J Ped Surg, 31:1138-41, (1996).

11) Yu J, Zhao Y, Holterman MJ, Venton DL (1999), Combinatorial search of substituted

beta-cyclodextrins for phosphatase-like activity. Bioorg Med Chem Lett; 9(18): 2705-10.

12) Chin A, Stich D, White F, Radhakrishnan J and Holterman MJ (2001) Paraneoplastic

pemphigus and bronchiolitis obliterans associated with a mediastinal mass. J Ped. Surg.,

2001 Dec 36 (12):E22.

13) Rao S, Vasu C, Martinez O, Kaithamana S, Prabhakar BS and Holterman MJ. (2001)

Targeted delivery of anti-CTLA4 antibody downregulates T cell function in vitro and in

vivo. Clin. Immunol.2001 Nov 101(2): 136-145.

14) Vasilevko V, Ghochikyan A, Holterman MJ, Agadjanyan MG., CD80 (B7-1) and CD86

(B7-2) are functionally equivalent in the initiation and maintenance of CD4+ T-cell proliferation

after activation with suboptimal doses of PHA. DNA Cell Biol 2002 Mar;

21(3): 137-49.

15) Vasu C, Wang A, Gorla SR, Kaithamana S, Prabhakar BS and Holterman M.J. CD80

C-domain enhances T cell inhibition by increasing binding to CTLA-4 (CD152) Int Immunol.

2003 Feb; 15(2):167-75.

16) Vasu C, Dogan RE, Holterman M.J. and Prabhakar BS. Selective induction of dendritic cells using GM-CSF, but not Flt3-L, activates thyroglobulin specific CD4+/CD25+ T cells and suppresses experimental autoimmune thyroiditis J Immunol. 2003 Jun 1;170(11):5511-22 17) Dogan RN, Vasu C, Holterman MJ, Prabhakar BS. Absence of IL-4, and not Suppres-sion of Th2 Response, Prevents Development of Experimental Autoimmune Graves’ Dis-ease. J Immunol. 2003 Feb 15; 170(4):2195-204. 18) Vasu C, Gorla SR, Prabhakar BS and Holterman MJ. (2003) Targeted engagement of CTLA-4 prevents autoimmune thyroiditis, Int. Immunol Int Immunol. 2003 May; 15(5):641-54. 19) Y J, Zhao Y, Holterman MJ, Venton DL. (2002) Cocaine detoxification by combinatori-ally substituted beta-cyclodextrin libraries. Biorg Med Chem. 2002 Oct; 10 (10):3291-9. 20) Yu J, Bakhos L, Chang L. Holterman MJ, Klein WL, Venton DL. (2002) Per-6-sub-stitued beta-cycodextrin libraries inhibit formation of beta-amyloid-peptide (A beta)-de-rived, soluble oligomers. J Mol Neurosci. 2002 Aug-Oct; 19(1-2):51-5. 21) Agadjanyan MG, Chattergoon MA, Holterman MJ, Monzavi-Karbassi B, Kim JJ, Dentchev T, Wilson D, Ayyavoo V, Montaner LJ, Kieber-Emmons T, Sekaly RP, Weiner DB. Costimulatory molecule immune enhancement in a plasmid vaccine model is regu-lated in part through the Ig constant-like domain of CD80/86. J Immunol. 2003 Oct 15; 171(8):4311-9. 22) Holterman MJ, Holterman AL, Carrol R, John E, Testa G, Sankary H, Cohen M, Grevi-ous M, Abcarian HA, Benedetti E. Living-related bowel transplantation to treat short bowel syndrome in a four-year-old child: a case report. J Pediatr Surg. 2003 Dec; 38(12):1763-5. 23) Vasu C, Holterman MJ, Prabhakar BS. Modulation of dendritic cell function and cy-tokine production to prevent thyroid autoimmunity. Autoimmunity. 2003 Sep-Nov; 36(6- 7):389-96. 24) Abdulla R, Blew GA and Holterman MJ, Cardiovascular embryology. Pediatr Cardiol. 2004 May-Jun; 25(3):191-200.

25) Short JJ, Pereboev AV, Kawakami Y, Vasu C, Holterman MJ, Curiel DT. Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virol-ogy. 2004 May 1; 322(2):349-59. 26) Vasu C, Prabhakar BS, Holterman MJ. Targeted CTLA-4 engagement induces CD4+CD25+CTLA-4high T regulatory cells with target (allo)antigen specificity. J Im-munol. 2004 Aug 15; 173(4):2866-76. 27) Talisetti A, Jelnin V, Ruiz C, John E, Benedetti E, Testa G, Holterman AL, Holterman MJ: Electron Beam CT scan is a Valuable and Safe Imaging Tool for the Pediatric Surgi-cal Patient J Pediatr Surg. 2004 Dec;39(12):1859-62. 28) Holterman AL, Holterman MJ, Jacobsen G, Berger R, Horgan S: Laparoscopic ad-justable gastric banding for the treatment of adolescent morbid obesity in the US: A safe alternative to gastric bypass. J Pediatr Surg. 2005 Jan; 40(1):86-90.

29) Testa G, Panaro F, Schena S, Holterman M, Abcarian H, Benedetti E. Living related

small bowel transplantation: donor surgical technique. Ann Surg. 2004 Nov; 240(5):779-

84.

30) Testa G, Holterman M, John E, Kecskes S, Abcarian H, Benedetti E. Combined living

donor liver/small bowel transplantation. Transplantation 2005; 79(10): 1401-1404.

31) Talisetti, A, Testa G, Holterman M, John E, Kecskes S, Benedetti E, Successful treatment

of posttransplant lymphoproliferative disorder with removal of small bowel graft

and subsequent second bowel transplant. J Pediatr Gastroenterol Nutr. 2005 Sep;

41(3):354-6.

32) Porubsky M, Testa G, John E, Holterman M, Tsou M, Benedetti E, Pattern of growth

after pediatric living-donor small bowel transplantation. Pediatr Transplant. 2006 Sep;

10(6):701-6.

33) Benedetti E, Holterman M, Asolati M, Di Domenico S, Oberholzer J, Sankary H, Abcarian

H, Testa G. Living related segmental bowel transplantation from experimental to

standardized procedure. Ann Surg. 2006 Nov;244(5):694-9

34) Short JJ, Vasu C, Holterman MJ, Curiel DT, Pereboev A. Members of adenovirus

species B utilizes CD80 and CD86 as cellular attachment receptors. Virus Res. 2006 Dec;

122(1-2):144-53.

35) Dillard BE 3rd, Gorodner V, Galvani C, Holterman M, Browne A, Gallo A, Horgan S,

Le Holterman AX. Initial experience with the adjustable gastric band in morbidly obese

US adolescents and recommendations for further investigation. J Pediatr Gastroenterol

Nutr. 2007 Aug; 45(2):240-6.

36) Li R, Perez N, Subha K-M, Prabhakar BS, Holterman MJ, Vasu C. Enhanced engagement

of CTLA-4 induces antigen specific CD4+CD25+Foxp3+ and CD4+CD25-TGFbeta1+

adaptive regulatory T cells. J Immunol. 2007 Oct 15;179(8):5191-203

37) Dingeldein MW, Kane D, Kim AW, Kabre R, Pescitelli MJ Jr,, Holterman MJ. Bilateral

intrathoracic kidneys and adrenal glands associated with posterior congenital diaphragmatic

hernias. Ann Thorac Surg. 2008 Aug; 86(2):651-4.

38) Zhao Y, Lin B, Darflinger R, Zhang Y, Holterman MJ, Skidgel RA. Human cord blood

stem cell-modulated regulatory T lymphocytes reverse the autoimmune-caused type 1

diabetes in nonobese diabetic (NOD) mice. PLoS ONE. 2009; 4(1):e4226. Epub 2009 Jan

19.

39) Dingeldein MW, Lu CY, Kim AW, Ostric S, Liptay MJ, Holterman MJ. Simultaneous

costal cartilage-sparing modified Ravitch procedure and latissimus dorsi transfer for

chest wall deformity repair in Poland’s syndrome. J Pediatr Surg. 2009 Jan; 44(1):e29-32.

40) Lee DD, Hollinger EF, Kim AW, Holterman MJ. Persistent hypoglycemia in a child with

a gastrocolic fistula–an unexpected presentation of leucine-sensitive hypoglycemia. J

Pediatr Surg. 2009 Apr;44(4):E13-6

41) Holterman AX, Browne A, Tussing L, Gomez S, Phipps A, Browne N, Stahl C, Holterman

  1. A prospective trial for laparoscopic adjustable gastric banding in morbidly

obese adolescents: an interim report of weight loss, metabolic and quality of life outcomes.

J Pediatr Surg. 2010 Jan; 45(1):74-8; discussion 78-9.

42) Jayaraman S, Patel T, Patel V, Ajani S, Garza R, Jayaraman A, Kwon S, Singh R, Rondelli

D, Prabhakar BS, Holterman M. Transfusion of nonobese diabetic mice with allogeneic

newborn blood ameliorates autoimmune diabetes and modifies the expression of selected

immune response genes. J Immunol. 2010 Mar 15; 184(6):3008-15. Epub 2010

Feb 17.

43) Zhao Y, Lin B, Dingeldein M, Guo C, Hwang D, Holterman MJ. New type of human

blood stem cell: a double-edged sword for the treatment of type 1 diabetes. Transl Res.

2010 May; 155(5):211-6. Epub 2010 Feb 12.

44) Karumuthil-Melethil S, Perez N, Li R, Prabhakar BS, Holterman MJ, Vasu C. Dendritic

cell directed CTLA-4 engagement during pancreatic β-cell antigen presentation delays

type 1 diabetes, J Immunol. 2010 Jun 15; 184(12):6695-708. Epub 2010 May 14

45) Zhao Y, Guo C, Hwang D, Lin B, Dingeldein M, Mihailescu D, Sam S, Sidhwani S,

Zhang Y, Jain S, Skidgel RA, Prabhakar BS, Mazzone T, Holterman MJ. Selective destruction

of mouse islet beta cells by human T lymphocytes in a newly-established humanized

type 1 diabetic model. Biochem Biophys Res Commun. 2010 Sep 3;

399(4):629-36. Epub 2010 Aug 4.

46) Holterman MJ, Le Holterman AX, Browne AF., Pediatric Obesity. Surg Clin North Am.

2012 Jun; 92(3):559-82, Review.

47) Zhao Y, Jiang Z, Zhao T, Ye M, Hu C, Yin Z, Li H, Zhang Y, Diao Y, Li Y, Chen Y, Sun

X, Fisk MB, Skidgel R, Holterman M, Prabhakar B, Mazzone T., Reversal of type 1 diabetes

via islet beta cell regeneration following immune modulation by cord blood-derived

multipotent stem cells. BMC Med. 2012 Jan 10; 10(1):3.

48) Holterman AX, Holterman M, Browne A, Henriques S, Guzman G, Fantuzzi G Patterns

of surgical weight loss and resolution of metabolic abnormalities in superobese bariatric

adolescents. J Pediatr Surg. 2012 Sep;47(9):1633-9

49) Jayaraman S, Patel A, Jayaraman A, Patel V, Holterman M, Prabhakar B Transcriptome

analysis of epigenetically modulated genome indicates signature genes in manifestation

of type 1 diabetes and its prevention in NOD mice. PLoS One. 2013;8(1):

50) Holterman AX, Guzman G, Fantuzzi G, Wang H, Aigner K, Browne A, Holterman M.

Nonalcoholic fatty liver disease in severely obese adolescent and adult patients. Obesity.

2013 Mar; 21(3):591-7.

51) Bhattacharya P, Budnick I, Singh M, Thiruppathi M, Alharshawi K, Elshabrawy H,

Holterman MJ, Prabhakar BS. Dual Role of GM-CSF as a Pro-Inflammatory and a

Regulatory Cytokine: Implications for Immune Therapy. J Interferon Cytokine Res. 2015

Aug;35(8):585-99

52) Gubareva EA, Sjöqvist S, Gilevich IV, Sotnichenko AS, Kuevda EV, Lim ML, Feliu N,

Lemon G, Danilenko KA, Nakokhov RZ, Gumenyuk IS, Grigoriev TE, Krasheninnikov

SV, Pokhotko AG, Basov AA, Dzhimak SS, Gustafsson Y, Bautista G, Beltran Rodríguez

A, Pokrovsky VM, Jungebluth P, Chvalun SN, Holterman MJ, Taylor DA, Macchiarini

  1. Orthotopic transplantation of a tissue engineered diaphragm in rats. Biomaterials. 2015

Nov 14; 77:320-335.

53) Ejaz A, Patel P, Gonzalez-Heredia R, Holterman M, Elli EF, Kanard R., Laparoscopic

sleeve gastrectomy as first-line surgical treatment for morbid obesity among adolescents,

J Pediatr Surg. 2016 Sep 3.

54) Aprahamian CJ, Nashad HH, DiSomma NM, Elger BM, Esparaz JR, McMorrow TJ,

Shadid AM, Kao AM, Holterman MJ, Kanard RC, Pearl RH Treatment of subcutaneous

abscesses in children with incision and loop drainage: A simplified method of care. J Pediatr

Surg. 2016 Dec 30.

55) Gargiulo C, Pham VH, Nguyen CDK, Vo TLH, Duy TH, et al. (2016) A Unique Case of

Crossover Second Toe Syndrome Treated by Autologous Peripheral Blood Stem Cells. J

Autoimmune Disord 3:1.

56) Gargiulo C, Pham VH, Thao HD, Kieu NCD, Shiffman,M, Holterman MJ and Aityan SK

(2016) Human Peripheral Blood Stem Cells and The Glycemic Index Diet can be a Solution

to Diabetes Mellitus Type 2. J Regen Med 5:2.

57) Jayaraman A, Soni A, Prabhakar BS, Holterman M, Jayaraman S. (2017) The epigenetic

drug Trichostatin A ameliorates experimental autoimmune encephalomyelitis via T cell

tolerance induction and impaired influx of T cells into the spinal cord. Neurobiol Dis.

2017 Jul 20;108:1-12.

BOOK CHAPTERS:

1) Parham P., Engelhard VH, Herman A, Holmes N, Holterman MJ, and Ways J.:!

“Biochemical approaches to understanding the structure and function of class I MHC

(HLA – A, B, C) molecules.” In Lymphocyte Surface Antigens, series: Perspectives in

Immunology and Histocompatibility, 6:1, (1984).

2) Holterman MJ, Le AT, and Engelhard VH: “Weak stimulation of murine cytolytic T

cells by human class I molecules maps to the a1 and a2 domains.” In Immunobiology of

HLA Volume II: Dupont, B. (ed), Springer-Verlag, New York, p. 140, and (1988).

3) Engelhard VH, Bernhard, EJ, Holterman MJ, Le AT, Henderson R, Ridge JP, Strub S,

Barbosa J and Lacy E.: “Cytotoxic T cell responses against human class I molecules in

normal and HLA-A2.1 transgenic mice.” In Transgenic Mice and Mutants in MHC Research:

Egorav I, and David CS (ed), Springer-Verlag, Heidelberg, pp. 179-190, (1990).

4) Engelhard VH, Bernhard EJ, Holterman MJ, Le AT, Henderson R, Ridge J, Strub S,

Barbosa J. and Lacy, E.: “T cell recognition of class I MHC molecules using gene transfection,

mutagenesis and class I transgenic mice.” In Immunology, Biochemistry, and

Biotechnology, Volume III, Molecular Mechanisms of Immune Regulation, Tyle P and

Srivastava R (ed), VCH Publishers, New York, (1991)

5) Benedetti E, Panaro F, Holterman M and Abcarian H., “Surgical approaches and intestinal

transplantation”, in Best Practice and Research, Clinical Gastroenterology, Vol 17,

No. 6, pp.1017-1040 (2003).

6) Browne A and Holterman MJ, “Placement of the Adjustable Gastric Band”, in Holcomb

et al: Atlas of Pediatric Laparoscopy and Thoracoscopy, 2008.

7) Benedetti E, Holterman MJ and Testa G,” Intestinal Transplantation – The Donor”, in

Gruessner, Living Donor Organ Transplantation, 2008.

8) Holterman MJ, Holterman AL, Browne AF, “Pediatric Obesity”, Surg Clin North Am.

June 2012

9) Holterman, MJ, Holterman AL and Browne, AF, “Bariatric Surgery in Adolescents”, In

Operative Pediatric Surgery, Ziegler M, et. al. editors, 2014 Service to the University

Department of Surgery-UIC

Journal Reviewer

Journal of Immunology

Journal of Pediatric Surgery

Frontiers in Pediatrics

Officer in National Organization

Clinical Councilor, American Assoc. of Clinical Anatomy, 2005-2007

Service for National Organizations

Publication Committee, American Academy of Pediatrics, Surgical Section, 2007-2009

Committee for Childhood Obesity, American Association of Pediatric Surgery, 2009-present

Chair, 2016-2018.

Finance Committee, American Association of Pediatric Surgery, 2010-2012

Program Committee, Pacific Association of Pediatric Surgeons, 2011-present

Program Committee Chairman, Pacific Association of Pediatric Surgeons 2014-2016

 Patents and Inventions:

7,527,972, Uses of bispecific antibody coated dendritic cells pulsed with antigens and GM-CSF in immune regulation, Prabhakar BS, Vasu C, Holterman MJ, Merrigioli MN

7446189, Nucleic acids encoding mutant human CD80 and compositions comprising the same. Weiner, D, Sekaly RP, Agadjanyan M and Holterman MJ

UIC-2010-031 “Stem Cell Immune modulation and Its Molecular Mechanisms”.

 

 

REGISTRATION FEES

Register for Aesthetics Surgery Conference “Live Surgery”

IN-PERSON REGISTRATION FOR SURGEONS
Early Registration
1000 €

After October 10, 2022
1500 €

REGISTER NOW

IN-PERSON REGISTRATION FOR RESIDENTS 
Early Registration 
450 €
After October 10, 2022
600 €

REGISTER NOW

VIRTUAL  REGISTRATION
09:00 am – 06:00 pm GMT +3

Early Registration
300 €

REGISTER NOW

SPONSORS - MEETING PARTNERS

Cancellation Policy

All cancellations shall be made via e-mail.
%50 of the total amount will be reimbursed if the cancellation is made before October 04, 2022.
No cancellation will be valid after October 04, 2022.
All type of registration amounts are inclusive of VAT.